Ultragenyx Pharmaceutical annual shareholders’ equity
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ultragenyx Pharmaceutical Shareholders’ Equity Growth & History (RARE)
Ultragenyx Pharmaceutical's shareholders’ equity was −$80.0M for fiscal 2025.
View full Ultragenyx Pharmaceutical company overviewUltragenyx Pharmaceutical annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$80.0M | −$335.0M | — |
| 2024 | 2024-12-31 | $255.0M | −$20.0M | −7.27% |
| 2023 | 2023-12-31 | $275.0M | −$77.0M | −21.88% |
| 2022 | 2022-12-31 | $352.0M | −$570.6M | −61.85% |
| 2021 | 2021-12-31 | $922.6M | −$231.8M | −20.08% |
| 2020 | 2020-12-31 | $1.15B | $500.6M | +76.57% |
| 2019 | 2019-12-31 | $653.8M | $44.9M | +7.37% |
| 2018 | 2018-12-31 | $608.9M | $225.5M | +58.80% |
| 2017 | 2017-12-31 | $383.5M | −$90.5M | −19.10% |
| 2016 | 2016-12-31 | $474.0M | −$57.1M | −10.75% |
| 2015 | 2015-12-31 | $531.1M | $346.1M | +187.16% |
| 2014 | 2014-12-31 | $184.9M | $259.8M | — |
| 2013 | 2013-12-31 | −$74.8M | −$47.8M | — |
| 2012 | 2012-12-31 | −$27.0M | — | — |
Ultragenyx Pharmaceutical quarterly shareholders’ equity
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$291.0M | −$442.0M | — |
| Q1 2026 | 2026-03-31 | −$236.0M | −$380.0M | — |
| Q4 2025 | 2025-12-31 | −$80.0M | −$335.0M | — |
| Q3 2025 | 2025-09-30 | $9.2M | −$337.7M | −97.36% |
| Q2 2025 | 2025-06-30 | $151.0M | −$281.4M | −65.08% |
| Q1 2025 | 2025-03-31 | $144.0M | $3.7M | +2.66% |
| Q4 2024 | 2024-12-31 | $255.0M | −$20.0M | −7.27% |
| Q3 2024 | 2024-09-30 | $346.8M | $315.1M | +993.61% |
| Q2 2024 | 2024-06-30 | $432.4M | $303.4M | +235.13% |
| Q1 2024 | 2024-03-31 | $140.3M | −$80.2M | −36.38% |
| Q4 2023 | 2023-12-31 | $275.0M | −$77.0M | −21.88% |
| Q3 2023 | 2023-09-30 | $31.7M | −$437.1M | −93.24% |
| Q2 2023 | 2023-06-30 | $129.0M | −$549.0M | −80.97% |
| Q1 2023 | 2023-03-31 | $220.5M | −$575.9M | −72.32% |
| Q4 2022 | 2022-12-31 | $352.0M | −$570.6M | −61.85% |
| Q3 2022 | 2022-09-30 | $468.8M | −$464.8M | −49.79% |
| Q2 2022 | 2022-06-30 | $678.1M | −$294.1M | −30.25% |
| Q1 2022 | 2022-03-31 | $796.4M | −$258.2M | −24.48% |
| Q4 2021 | 2021-12-31 | $922.6M | −$231.8M | −20.08% |
| Q3 2021 | 2021-09-30 | $933.7M | $267.5M | +40.15% |
| Q2 2021 | 2021-06-30 | $972.2M | $276.6M | +39.76% |
| Q1 2021 | 2021-03-31 | $1.05B | $445.4M | +73.12% |
| Q4 2020 | 2020-12-31 | $1.15B | $500.6M | +76.57% |
| Q3 2020 | 2020-09-30 | $666.2M | −$61.1M | −8.40% |
| Q2 2020 | 2020-06-30 | $695.6M | −$124.2M | −15.15% |
| Q1 2020 | 2020-03-31 | $609.1M | −$277.6M | −31.30% |
| Q4 2019 | 2019-12-31 | $653.8M | $44.9M | +7.37% |
| Q3 2019 | 2019-09-30 | $727.3M | $64.7M | +9.76% |
| Q2 2019 | 2019-06-30 | $819.8M | $115.8M | +16.45% |
| Q1 2019 | 2019-03-31 | $886.7M | $163.1M | +22.53% |
| Q4 2018 | 2018-12-31 | $608.9M | $225.5M | +58.80% |
| Q3 2018 | 2018-09-30 | $662.6M | $297.0M | +81.26% |
| Q2 2018 | 2018-06-30 | $704.0M | $274.5M | +63.92% |
| Q1 2018 | 2018-03-31 | $723.7M | $235.2M | +48.15% |
| Q4 2017 | 2017-12-31 | $383.5M | −$90.5M | −19.10% |
| Q3 2017 | 2017-09-30 | $365.6M | −$90.3M | −19.81% |
| Q2 2017 | 2017-06-30 | $429.5M | −$14.4M | −3.25% |
| Q1 2017 | 2017-03-31 | $488.5M | −$1.3M | −0.27% |
| Q4 2016 | 2016-12-31 | $474.0M | −$57.1M | −10.75% |
| Q3 2016 | 2016-09-30 | $455.9M | −$120.9M | −20.96% |
| Q2 2016 | 2016-06-30 | $443.9M | $124.6M | +39.03% |
| Q1 2016 | 2016-03-31 | $489.8M | $148.7M | +43.59% |
| Q4 2015 | 2015-12-31 | $531.1M | $346.1M | +187.16% |
| Q3 2015 | 2015-09-30 | $576.8M | $377.4M | +189.36% |
| Q2 2015 | 2015-06-30 | $319.3M | $166.2M | +108.57% |
| Q1 2015 | 2015-03-31 | $341.1M | $175.4M | +105.85% |
| Q4 2014 | 2014-12-31 | $184.9M | $259.8M | — |
| Q3 2014 | 2014-09-30 | $199.3M | — | — |
| Q2 2014 | 2014-06-30 | $153.1M | — | — |
| Q1 2014 | 2014-03-31 | $165.7M | — | — |
| Q4 2013 | 2013-12-31 | −$74.8M | — | — |
Ultragenyx Pharmaceutical shareholders’ equity trends
Over the last five fiscal years, Ultragenyx Pharmaceutical's shareholders’ equity decreased from $1.15B to −$80.0M, a change of −$1.23B. The latest reported quarter, Q2 2026, shows −$291.0M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ultragenyx Pharmaceutical source filings ↗